AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Recruiting
- Conditions
- Heart DiseasesCardiovascular DiseasesHeart Failure
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06336330
- Locations
- 🇩🇪
Research Site, Wermsdorf, Germany
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT06336356
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Phase 4
Active, not recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 632
- Registration Number
- NCT06327815
- Locations
- 🇨🇳
Research Site, Zhuji, China
Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
Completed
- Conditions
- Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2506
- Registration Number
- NCT06324734
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 553
- Registration Number
- NCT06321731
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Recruiting
- Conditions
- Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06314282
- Locations
- 🇸🇦
Research Site, Riyadh, Saudi Arabia
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT06311760
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Phase 3
Recruiting
- Conditions
- Asthma
- Interventions
- Combination Product: BDA MDICombination Product: AS MDI
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 440
- Registration Number
- NCT06307665
- Locations
- 🇿🇦
Research Site, Welkom, South Africa
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Phase 3
Recruiting
- Conditions
- Heart Failure and Impaired Kidney Function
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4800
- Registration Number
- NCT06307652
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT06304961
- Locations
- 🇩🇪
Research Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath